Upload Avatar (500 x 500)
Xu Yang
Pharmaceutical Sciences
Peking University
Beijing
Language: Chinese, English
Real-World
Safety
Efficacy
Evaluation
Drugs
Medical Devices
Pharmacovigilance
Clinical Outcomes
Healthcare
Regulatory Science
Areas of Focus
- Real-world safety and efficacy evaluation of drugs and medical devices
Work Experience
- 2023.08-present - Peking University - Department of Pharmacy Administration and Clinical Pharmacy - Associate Researcher
- 2021.06-2023.07 - Peking University - Clinical Research Institute - Associate Researcher
- 2019.02-2021.02 - Karolinska Institute - Department of Clinical Epidemiology and Biostatistics - Postdoctoral Researcher
- 2018.09-2019.01 - Peking University - National Institute of Health and Medical Big Data - Assistant Researcher
Academic Background & Achievements
- 2018 PhD in Medicine: Peking University
- 2015 MSc in Science: Peking University
- 2013 BSc in Science/Economics: Peking University
Publications
- Poor recognition and undertreatment of anemia in patients with chronic kidney disease managed in primary care, Xu Y*, Evans M, Mazhar F, et al., 2023
- Long-term Visit-to-Visit Variability in Hemoglobin A(1c) and Kidney-Related Outcomes in Persons With Diabetes, Xu Y*, Dong S, Fu EL, Sjölander A, Grams ME, Selvin E, Carrero JJ, 2023
- National incidence and mortality of hospitalized sepsis in China, Weng L#, Xu Y#, Yin P#, Wang Y, Chen Y, Liu W, Li S, Peng JM, Dong R, Hu XY, Jiang W, Wang CY, Gao P, Zhou MG, Du B and for the China Critical Care Clinical Trials G, 2023
- GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes, Xu Y#*, Fu EL#, Clase CM, Mazhar F, Jardine MJ, Carrero JJ, 2022
- Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes, Xu Y, Fu EL, Trevisan M, Jernberg T, Sjölander A, Clase CM, Carrero JJ, 2022
- Burden and causes of hospital admissions and readmissions in patients undergoing hemodialysis and peritoneal dialysis: a nationwide study, Xu Y#, Li L#, Evans M, Xu H, Lindholm B, Carrero JJ, 2021
- Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease, Xu Y, Evans M, Soro M, Barany P, Carrero JJ, 2021
- Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study, Xu Y, Evans M, Barany P, James G, Sjölander A and Carrero JJ, 2021
- Glycemic Control and the Risk of Acute Kidney Injury in Patients With Type 2 Diabetes and Chronic Kidney Disease: Parallel Population-Based Cohort Studies in U.S. and Swedish Routine Care, Xu Y*, Surapaneni A, Alkas J, Evans M, Shin J-I, Selvin E, Chang A, Grams ME, Carrero JJ, 2020
- Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China, Xu Y, Wang T, Yang Z, Lin H, Shen P, Zhan S, 2020
Awards
- 2023-2024: Best Abstract at the 60th European Renal Association Congress
